Gaush Meditech's (HKG:2407) subsidiary Gaush Teleon obtained a class II medical device registration certificate for its self-developed intraocular lens implant system from the Guangdong Provincial Medical Products Administration, a Wednesday Hong Kong bourse filing said.

As of now, all cataract surgery therapies generally require intraocular lens implantation to treat problems like blindness due to cataracts, and high myopia, the filing said.

Gaush Teleon's intraocular lens implant system can be applied for cataract surgery and also in the implantation of phakic intraocular lenses for myopia treatment.

The ophthalmology medical business company's shares closed nearly 6% lower on Wednesday.